TheraRadar
← Back
Data updated: Jun 28, 2026

DEY

Generics
Respiratory Execution: Excellent

DEY is a generic drug manufacturer focused on Respiratory.

1986
Since
6
Drugs
-
Trials
0
New Drugs (2yr)

DEY at a Glance

  • Strong track record with 100% execution quality across 6 trials
  • Fast trial execution (20 months median completion)

DEY's Key Drugs

DEY's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

DEY's Recent FDA Approvals

New NDA/BLA approvals for DEY over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

DEY's Therapeutic Areas

DEY's approved drugs and pipeline span 1 therapeutic area, led by Respiratory. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Respiratory 100%
0 drugs Phase 2: 5 Phase 1: 1

DEY's Top Competitors

DEY's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and GSK. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Novartis big-pharma
Respiratory
Merck big-pharma
Respiratory
GSK big-pharma
Respiratory
Bayer big-pharma
Respiratory
AstraZeneca big-pharma
Respiratory

DEY Pipeline Snapshot

DEY has 6 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 5 Phase 2 and 1 Phase 1.

0
Phase 3
5
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Respiratory pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/0 completed
  • • Speed: 20 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges